Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accuray Incorporated stock logo
ARAY
Accuray
$1.64
+4.5%
$1.59
$1.28
$2.95
$168.94M1.3710,406 shs606,034 shs
CVRx, Inc. stock logo
CVRX
CVRx
$6.96
+4.3%
$7.98
$4.30
$18.55
$181.47M1.39333,251 shs347,678 shs
LENSAR, Inc. stock logo
LNSR
LENSAR
$13.58
+0.1%
$13.90
$3.50
$17.31
$160.14M0.5679,028 shs121,964 shs
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$3.71
+10.7%
$2.94
$2.03
$6.48
$65.06M0.8112,909 shs79,504 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accuray Incorporated stock logo
ARAY
Accuray
+4.46%-5.75%+3.80%-20.00%+8.61%
CVRx, Inc. stock logo
CVRX
CVRx
+4.35%-0.43%+3.42%-49.16%-6.58%
LENSAR, Inc. stock logo
LNSR
LENSAR
+0.15%-2.86%-2.37%+43.40%+224.11%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
+10.75%-1.59%+35.90%+5.10%-25.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Accuray Incorporated stock logo
ARAY
Accuray
2.5294 of 5 stars
0.02.00.04.63.31.71.9
CVRx, Inc. stock logo
CVRX
CVRx
2.813 of 5 stars
3.42.00.00.02.74.20.6
LENSAR, Inc. stock logo
LNSR
LENSAR
1.8357 of 5 stars
2.05.00.00.03.32.50.0
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.783 of 5 stars
0.02.00.00.04.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accuray Incorporated stock logo
ARAY
Accuray
0.00
N/AN/AN/A
CVRx, Inc. stock logo
CVRX
CVRx
2.71
Moderate Buy$14.50108.33% Upside
LENSAR, Inc. stock logo
LNSR
LENSAR
2.00
Hold$15.0010.46% Upside
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NVNO, LNSR, CVRX, and ARAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
CVRx, Inc. stock logo
CVRX
CVRx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.00
5/9/2025
CVRx, Inc. stock logo
CVRX
CVRx
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.00
4/8/2025
CVRx, Inc. stock logo
CVRX
CVRx
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $14.00
4/8/2025
CVRx, Inc. stock logo
CVRX
CVRx
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $18.00
3/24/2025
LENSAR, Inc. stock logo
LNSR
LENSAR
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/24/2025
LENSAR, Inc. stock logo
LNSR
LENSAR
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$16.00 ➝ $15.00
2/28/2025
LENSAR, Inc. stock logo
LNSR
LENSAR
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $16.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accuray Incorporated stock logo
ARAY
Accuray
$465.25M0.36N/AN/A$0.45 per share3.64
CVRx, Inc. stock logo
CVRX
CVRx
$52.87M3.43N/AN/A$2.73 per share2.55
LENSAR, Inc. stock logo
LNSR
LENSAR
$57.07M2.81N/AN/A$2.97 per share4.57
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A$3.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accuray Incorporated stock logo
ARAY
Accuray
-$15.55M-$0.05N/A13.67N/A-0.96%-9.75%-0.93%8/13/2025 (Estimated)
CVRx, Inc. stock logo
CVRX
CVRx
-$59.97M-$2.18N/AN/AN/A-116.91%-93.06%-51.78%8/4/2025 (Estimated)
LENSAR, Inc. stock logo
LNSR
LENSAR
-$14.38M-$4.85N/AN/A-34.03%-49.02%-21.12%8/6/2025 (Estimated)
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$23.52M-$1.18N/AN/AN/AN/A-48.72%-45.96%7/30/2025 (Estimated)

Latest NVNO, LNSR, CVRX, and ARAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
CVRx, Inc. stock logo
CVRX
CVRx
-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million
5/8/2025Q1 2025
LENSAR, Inc. stock logo
LNSR
LENSAR
-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 million
4/30/2025Q3 2025
Accuray Incorporated stock logo
ARAY
Accuray
-$0.05-$0.01+$0.04-$0.01$101.53 million$113.24 million
4/30/2025Q1 2025
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A-$0.22N/A-$0.22N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Accuray Incorporated stock logo
ARAY
Accuray
N/AN/AN/AN/AN/A
CVRx, Inc. stock logo
CVRX
CVRx
N/AN/AN/AN/AN/A
LENSAR, Inc. stock logo
LNSR
LENSAR
N/AN/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accuray Incorporated stock logo
ARAY
Accuray
3.51
1.62
0.88
CVRx, Inc. stock logo
CVRX
CVRx
0.69
12.06
10.23
LENSAR, Inc. stock logo
LNSR
LENSAR
N/A
3.37
2.10
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A
22.01
22.01

Institutional Ownership

CompanyInstitutional Ownership
Accuray Incorporated stock logo
ARAY
Accuray
64.08%
CVRx, Inc. stock logo
CVRX
CVRx
75.27%
LENSAR, Inc. stock logo
LNSR
LENSAR
40.15%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
34.71%

Insider Ownership

CompanyInsider Ownership
Accuray Incorporated stock logo
ARAY
Accuray
4.23%
CVRx, Inc. stock logo
CVRX
CVRx
13.90%
LENSAR, Inc. stock logo
LNSR
LENSAR
38.52%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Accuray Incorporated stock logo
ARAY
Accuray
1,040103.01 million98.48 millionOptionable
CVRx, Inc. stock logo
CVRX
CVRx
16026.07 million21.12 millionOptionable
LENSAR, Inc. stock logo
LNSR
LENSAR
11011.79 million7.14 millionOptionable
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
1917.54 million14.73 millionOptionable

Recent News About These Companies

enVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last year
enVVeno Medical files $100M mixed securities shelf
enVVeno Medical presents one-year data from VenoValve trial
enVVeno Medical presents two-year follow-up data from VenoValve trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Accuray stock logo

Accuray NASDAQ:ARAY

$1.64 +0.07 (+4.46%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.62 -0.02 (-1.16%)
As of 05/27/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

CVRx stock logo

CVRx NASDAQ:CVRX

$6.96 +0.29 (+4.35%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$6.80 -0.16 (-2.30%)
As of 05/27/2025 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

LENSAR stock logo

LENSAR NASDAQ:LNSR

$13.58 +0.02 (+0.15%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$13.52 -0.05 (-0.41%)
As of 05/27/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

enVVeno Medical stock logo

enVVeno Medical NASDAQ:NVNO

$3.71 +0.36 (+10.75%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.98 +0.27 (+7.28%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.